249 related articles for article (PubMed ID: 22292735)
1. Prognostic value of Bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving bacillus Calmette-Guerin immunotherapy.
Ajili F; Kaabi B; Darouiche A; Tounsi H; Kourda N; Chebil M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Feb; 36(1):31-9. PubMed ID: 22292735
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
3. Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with Bacillus Calmette-Guerin immunotherapy.
Ajili F; Manai M; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):320-4. PubMed ID: 23025650
[TBL] [Abstract][Full Text] [Related]
4. Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.
Ayari C; LaRue H; Hovington H; Decobert M; Harel F; Bergeron A; Têtu B; Lacombe L; Fradet Y
Eur Urol; 2009 Jun; 55(6):1386-95. PubMed ID: 19193487
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bladder cancer treated by BCG immunotherapy.
Ajili F; Kourda N; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Feb; 37(1):56-61. PubMed ID: 23383616
[TBL] [Abstract][Full Text] [Related]
6. The expression level of ligands for natural killer cell receptors predicts response to bacillus Calmette-Guerin therapy: a pilot study.
Yutkin V; Pode D; Pikarsky E; Mandelboim O
J Urol; 2007 Dec; 178(6):2660-4. PubMed ID: 17945285
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of angiogenesis in nonmuscle invasive bladder cancer as defined by microvessel density after immunohistochemical staining for CD34.
Ajili F; Kacem M; Tounsi H; Darouiche A; Enayfer E; Chebi M; Manai M; Boubaker S
Ultrastruct Pathol; 2012 Oct; 36(5):336-42. PubMed ID: 22574784
[TBL] [Abstract][Full Text] [Related]
8. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas.
Kato K; Kawashiri S; Yoshizawa K; Kitahara H; Yamamoto E
J Oral Pathol Med; 2008 Jul; 37(6):364-71. PubMed ID: 18410312
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613
[TBL] [Abstract][Full Text] [Related]
10. Bilharzial related, organ confined, muscle invasive bladder cancer: prognostic value of apoptosis markers, proliferation markers, p53, E-cadherin, epidermal growth factor receptor and c-erbB-2.
Haitel A; Posch B; El-Baz M; Mokhtar AA; Susani M; Ghoneim MA; Marberger M
J Urol; 2001 May; 165(5):1481-7. PubMed ID: 11342901
[TBL] [Abstract][Full Text] [Related]
11. Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancer.
Cormio L; Tolve I; Annese P; Saracino A; Zamparese R; Sanguedolce F; Bufo P; Battaglia M; Selvaggi FP; Carrieri G
Urol Oncol; 2010; 28(3):285-9. PubMed ID: 18976938
[TBL] [Abstract][Full Text] [Related]
12. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
[TBL] [Abstract][Full Text] [Related]
13. The impact of age and clinical factors in non-muscle-invasive bladder cancer treated with Bacillus Calmette Guerin therapy.
Ajili F; Darouiche A; Chebil M; Boubaker S
Ultrastruct Pathol; 2013 May; 37(3):191-5. PubMed ID: 23634793
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
15. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
16. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of Bcl-2 and Bax protein expression in the patients with oral squamous cell carcinoma.
Zhang M; Zhang P; Zhang C; Sun J; Wang L; Li J; Tian Z; Chen W
J Oral Pathol Med; 2009 Mar; 38(3):307-13. PubMed ID: 18710422
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
19. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
20. An analysis of the effect of statin use on the efficacy of bacillus calmette-guerin treatment for transitional cell carcinoma of the bladder.
Berglund RK; Savage CJ; Vora KC; Kurta JM; Cronin AM
J Urol; 2008 Oct; 180(4):1297-300; discussion 1300. PubMed ID: 18707737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]